- Home
- DKNG vs BGNE Comparison
DKNG vs BGNE Comparison
Compare DKNG & BGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DKNG
- BGNE
- Stock Information
- Founded
- DKNG 2012
- BGNE 2010
- Country
- DKNG United States
- BGNE Cayman Islands
- Employees
- DKNG N/A
- BGNE N/A
- Industry
- DKNG Services-Misc. Amusement & Recreation
- BGNE Biotechnology: Pharmaceutical Preparations
- Sector
- DKNG Consumer Discretionary
- BGNE Health Care
- Exchange
- DKNG Nasdaq
- BGNE Nasdaq
- Market Cap
- DKNG 20.6B
- BGNE 21.0B
- IPO Year
- DKNG N/A
- BGNE 2016
- Fundamental
- Price
- DKNG $39.84
- BGNE $189.23
- Analyst Decision
- DKNG Strong Buy
- BGNE Buy
- Analyst Count
- DKNG 27
- BGNE 7
- Target Price
- DKNG $50.37
- BGNE $247.07
- AVG Volume (30 Days)
- DKNG 10.3M
- BGNE 281.8K
- Earning Date
- DKNG 11-07-2024
- BGNE 11-12-2024
- Dividend Yield
- DKNG N/A
- BGNE N/A
- EPS Growth
- DKNG N/A
- BGNE N/A
- EPS
- DKNG N/A
- BGNE N/A
- Revenue
- DKNG $4,605,784,000.00
- BGNE $3,351,304,621.00
- Revenue This Year
- DKNG $42.82
- BGNE $969.39
- Revenue Next Year
- DKNG $22.41
- BGNE $24.79
- P/E Ratio
- DKNG N/A
- BGNE N/A
- Revenue Growth
- DKNG 40.01
- BGNE 50.22
- 52 Week Low
- DKNG $28.69
- BGNE $126.97
- 52 Week High
- DKNG $49.57
- BGNE $248.16
- Technical
- Relative Strength Index (RSI)
- DKNG 54.94
- BGNE 31.72
- Support Level
- DKNG $38.10
- BGNE $189.60
- Resistance Level
- DKNG $43.33
- BGNE $209.29
- Average True Range (ATR)
- DKNG 1.46
- BGNE 6.42
- MACD
- DKNG 0.43
- BGNE -2.10
- Stochastic Oscillator
- DKNG 57.59
- BGNE 9.19
About DKNG DraftKings Inc.
DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number two or three revenue share position across states in which it competes. DraftKings is now live with online or retail sports betting in 27 states and iGaming in seven states, with both products available to around 40% of Canada's population. The company also operates a non-fungible token commissioned-based marketplace and develops and licenses online gaming products.
About BGNE BeiGene Ltd.
BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene's key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.